From Medscape Oncology

Coverage from the

Gastrointestinal Cancers Symposium (GICS) 2017

January 19 - 21, 2017; San Francisco, California

January 19 - 21, 2017 San Francisco, California

In Sunny LA, Prostate Cancer Patients Just Walk Away In a rare real-world study of adherence to active surveillance in Los Angeles, the percentage of men who are lost to follow-up is high, especially among poor patients.
Medscape Medical News, February 20, 2017
GICS 'Watch-and-Wait' Safe in Selected Rectal Cancer Patients In the largest series to date, survival was similar for rectal cancer patients who chose to 'watch-and-wait' and for those who underwent surgery.
Medscape Medical News, January 18, 2017

Conference News

GICS Biomarkers Identified for Celecoxib Chemoprevention in CRC
Medscape Medical News, January 26, 2017
GICS Cabozantinib for Carcinoid and Pancreatic NETs: 'Encouraging'
Medscape Medical News, January 25, 2017
GICS Nivolumab Continues to Boost Survival in Liver Cancer
Medscape Medical News, January 23, 2017
GICS Phase 2 Trials in Pancreatic Cancer: Missing the Mark
Medscape Medical News, January 23, 2017

GICS Nivolumab: New Treatment Option in Advanced Gastric Cancer
Medscape Medical News, January 20, 2017
GICS New Rx for Advanced Colorectal Cancer: Exercise
Medscape Medical News, January 19, 2017
GICS PET Scan to 'Fine Tune' Chemo for Esophageal Cancer
Medscape Medical News, January 18, 2017
GICS 'Watch-and-Wait' Safe in Selected Rectal Cancer Patients
Medscape Medical News, January 18, 2017

Popular News from GICS 2016

First Chemo 'Antidote' Cuts Deaths From 5-FU Toxicity The first and only approved antidote for severe toxicity related to a chemotherapy overdose dramatically reduces mortality.
Medscape Medical News, Feb 2, 2016
New Standard of Care in Metastatic Pancreatic Cancer? Liposomal irinotecan combined with fluorouracil and leucovorin should be the standard of care for patients with metastatic pancreatic cancer that has progressed on gemcitabine, say researchers.
Medscape Medical News, Feb 1, 2016
TTFields Plus Chemo Shows Benefit in Pancreatic Cancer A device that delivers tumor-treating fields (TTFields), recently approved for use in glioblastoma, is now showing benefit in advanced pancreatic cancer.
Medscape Medical News, Jan 26, 2016

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

GICS on Twitter

Previous Coverage